Associated Clinical and Laboratory Markers of Donor on Allograft Function After Heart Transplant

被引:13
|
作者
Braulio, Renato [1 ]
Sanches, Marcelo Dias [1 ]
Teixeira Junior, Antonio Lucio [1 ]
Nogueira Costa, Paulo Henrique [1 ]
Vieira Moreira, Maria da Consolacao [1 ]
Rocha, Monaliza Angela [1 ]
de Andrade, Silvio Amadeu [1 ]
Gelape, Claudio Leo [1 ]
机构
[1] Univ Fed Minas Gerais, Av Prof Alfredo Balena 110, BR-30130100 Belo Horizonte, MG, Brazil
关键词
Heart Transplantation; Tissue Donors; Biomarkers; Norepinephrine; Primary Graft Dysfunction; PRIMARY GRAFT FAILURE; MANAGEMENT; DYSFUNCTION; MORTALITY; IMPACT; RISK;
D O I
10.5935/1678-9741.20160025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Primary graft dysfunction is a major cause of mortality after heart transplantation. Objective: To evaluate correlations between donor-related clinical/biochemical markers and the occurrence of primary graft dysfunction/clinical outcomes of recipients within 30 days of transplant. Methods: The prospective study involved 43 donor/recipient pairs. Data collected from donors included demographic and echocardiographic information, noradrenaline administration rates and concentrations of soluble tumor necrosis factor receptors (sTNFR1 and sTNFR2), interleukins (IL-6 and IL-10), monocyte chemoattractant protein-1, C-reactive protein and cardiac troponin I. Data collected from recipients included operating, cardiopulmonary bypass, intensive care unit and hospitalization times, inotrope administration and left/right ventricular function through echocardiography. Results: Recipients who developed moderate/severe left ventricular dysfunction had received organs from significantly older donors (P=0.020). Recipients from donors who required moderate/high doses of noradrenaline (>0.23 mu g/kg/min) around harvesting time exhibited lower post-transplant ventricular ejection fractions (P=0.002) and required longer CPB times (P=0.039). Significantly higher concentrations of sTNFR1 (P=0.014) and sTNFR2 (P=0.030) in donors were associated with reduced intensive care unit times (<= 5 days) in recipients, while higher donor IL-6 (P=0.029) and IL-10 (P=0.037) levels were correlated with reduced hospitalization times (<= 25 days) in recipients. Recipients who required moderate/high levels of noradrenaline for weaning off cardiopulmonary bypass were associated with lower donor concentrations of sTNFR2 (P=0.028) and IL-6 (P=0.001). Conclusion: High levels of sTNFR1, sTNFR2, IL-6 and IL-10 in donors were associated with enhanced evolution in recipients. Allografts from older donors, or from those treated with noradrenaline doses >0.23 mu g/kg/min, were more frequently affected by primary graft dysfunction within 30 days of surgery.
引用
收藏
页码:89 / 97
页数:9
相关论文
共 50 条
  • [41] De Novo Donor Specific Antibodies (dnDSA) Is Associated with Cardiac Allograft Hypertrophy After Heart Transplantation (HT)
    Pereira, N. L.
    Valero, M. Jesus
    Wong, M.
    Kushwaha, S.
    Smith, B.
    Kremers, W.
    Gandhi, M.
    Richard, D.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S228 - S228
  • [42] Sympathetic reinnervation and allograft performance after orthotopic heart transplant.
    Bengel, F
    Schiepel, N
    Ueberfuhr, P
    Nekolla, SG
    Reichart, B
    Schwaiger, M
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 135P - 135P
  • [43] Donor-Specific HLA Alloantibodies: Long-Term Impact on Cardiac Allograft Vasculopathy and Mortality After Heart Transplant
    Kaczmarek, Ingo
    Deutsch, Marcus-Andre
    Kauke, Teresa
    Beiras-Fernandez, Andres
    Schmoeckel, Michael
    Vicol, Calin
    Sodian, Ralf
    Reichart, Bruno
    Spannagl, Michael
    Ueberfuhr, Peter
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2008, 6 (03) : 229 - 235
  • [44] THE HEART VS THE HOST: DONOR TRANSMISSION OF TOXOPLASMA GONDII AFTER HEART TRANSPLANT
    Threadgill, Ryan
    Drake, Matthew
    CHEST, 2019, 156 (04) : 1503A - 1503A
  • [45] The meaning of donor-specific antibodies after heart transplant
    Barten, Markus J.
    Zuckermann, Andreas
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2019, 24 (03) : 252 - 258
  • [46] PRE-TRANSPLANT COLLAGEN VASCULAR DISEASE IS ASSOCIATED WITH AN INCREASE IN CARDIAC ALLOGRAFT VASCULOPATHY AFTER HEART TRANSPLANTATION
    Harris, G.
    Nishihara, K.
    Shen, A.
    Levine, R.
    Hamilton, M.
    Kobashigawa, J.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2020, 68 : A34 - A34
  • [47] Spontaneous Donor Hypothermia is Independently Associated with Increased Risk of Primary Graft Dysfunction After Heart Transplant
    Han, J.
    Kransdorf, E. P.
    Rushakoff, J.
    Moayedi, Y.
    Henricksen, E.
    Lee, R.
    Luikart, H.
    Shalakhti, O.
    Benck, L.
    Malinoski, D.
    Kobashigawa, J. A.
    Teuteberg, J. J.
    Khush, K.
    Patel, J. K.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04): : S101 - S101
  • [48] Initiation of noninvasive surveillance for allograft rejection in heart transplant patients > 1 year after transplant
    Kewcharoen, Jakrin
    Kim, Jean
    Cummings, Mandi B.
    Leitner, Katie B.
    Suzuki, Erin M. B.
    Banerjee, Dipanjan
    Lum, Corey J.
    CLINICAL TRANSPLANTATION, 2022, 36 (03)
  • [49] Inflammatory Cytokines, Endothelial Function, and Chronic Allograft Vasculopathy in Children: An Investigation of the Donor and Recipient Vasculature After Heart Transplantation
    Fenton, M.
    Simmonds, J.
    Shah, V.
    Brogan, P.
    Klein, N.
    Deanfield, J.
    Burch, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 (05) : 1559 - 1568
  • [50] Prevalence and implications of donor-transmitted coronary allograft vasculopathy on outcomes of heart transplant recipients
    Estevez Loureiro, R.
    Crespo-Leiro, M. G.
    Calvino-Santos, R. A.
    Paniagua-Martin, M. J.
    Vazquez-Rodriguez, J. M.
    Salgado-Fernandez, J.
    Vazquez-Gonzalez, N.
    Rodriguez-Fernandez, J. A.
    Cuenca-Castillo, J. J.
    Castro-Beiras, A.
    EUROPEAN HEART JOURNAL, 2009, 30 : 137 - 138